Business Description
Enlivex Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011319527
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 31.07 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22 | |||||
3-Year EPS without NRI Growth Rate | -20.2 | |||||
3-Year FCF Growth Rate | -11.9 | |||||
3-Year Book Growth Rate | -12.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 21.67 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.92 | |||||
9-Day RSI | 51.86 | |||||
14-Day RSI | 53.89 | |||||
6-1 Month Momentum % | -67.86 | |||||
12-1 Month Momentum % | -25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.06 | |||||
Quick Ratio | 10.06 | |||||
Cash Ratio | 9.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | -6.26 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -66.11 | |||||
ROA % | -55.81 | |||||
ROIC % | -174.14 | |||||
3-Year ROIIC % | -684.15 | |||||
ROC (Joel Greenblatt) % | -259.41 | |||||
ROCE % | -52.43 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.08 | |||||
Price-to-Tangible-Book | 1.08 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.37 | |||||
EV-to-FCF | -0.38 | |||||
Price-to-Net-Current-Asset-Value | 1.22 | |||||
Price-to-Net-Cash | 1.37 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -54.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Enlivex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.091 | ||
Beta | 1.21 | ||
Volatility % | 95.4 | ||
14-Day RSI | 53.89 | ||
14-Day ATR (€) | 0.060661 | ||
20-Day SMA (€) | 1.196 | ||
12-1 Month Momentum % | -25 | ||
52-Week Range (€) | 1.05 - 3.92 | ||
Shares Outstanding (Mil) | 21.41 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Enlivex Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Enlivex Therapeutics Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Enlivex Therapeutics Ltd Frequently Asked Questions
What is Enlivex Therapeutics Ltd(STU:1BT)'s stock price today?
When is next earnings date of Enlivex Therapeutics Ltd(STU:1BT)?
Does Enlivex Therapeutics Ltd(STU:1BT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |